Sucampo Pharmaceuticals (NASDAQ:SCMP) had its target price boosted by equities research analysts at B. Riley from $14.00 to $18.00 in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s target price would indicate a potential upside of 26.76% from the stock’s previous close.
A number of other brokerages also recently issued reports on SCMP. BidaskClub raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. Finally, Maxim Group reaffirmed a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $16.40.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $14.20 on Wednesday. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.24. The stock has a market cap of $627.25, a PE ratio of 9.21, a PEG ratio of 4.00 and a beta of 1.47. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.
In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.13% of the company’s stock.
Several hedge funds have recently bought and sold shares of SCMP. Point72 Asset Management L.P. purchased a new position in shares of Sucampo Pharmaceuticals during the third quarter worth approximately $21,989,000. Rubric Capital Management LP purchased a new position in shares of Sucampo Pharmaceuticals during the second quarter worth approximately $6,068,000. Vanguard Group Inc. raised its stake in shares of Sucampo Pharmaceuticals by 48.9% during the first quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock worth $16,024,000 after acquiring an additional 478,226 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Sucampo Pharmaceuticals by 871.6% during the third quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after acquiring an additional 368,090 shares in the last quarter. Finally, Systematic Financial Management LP bought a new position in shares of Sucampo Pharmaceuticals in the second quarter worth approximately $1,648,000. 65.31% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals (SCMP) PT Raised to $18.00” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/06/sucampo-pharmaceuticals-scmp-pt-raised-to-18-00.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
What are top analysts saying about Sucampo Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals Inc. and related companies.